The U.S. Food and Drug Administration granted accelerated approvals to two cancer therapies this week. Dizal Pharmaceutical’s sunvozertinib (Zegfrovy) received approval for treating non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations after platinum-based chemotherapy. Simultaneously, Regeneron Pharmaceuticals gained approval for Lynozyfic (linvoseltamab), a bispecific antibody targeting BCMA, to treat relapsed and refractory multiple myeloma. These additions enhance the arsenal against these difficult-to-treat cancers and may offer new treatment options for patients with limited alternatives.